What is ATOS's health score?

ATOSSA THERAPEUTICS, INC. (ATOS) has a TradeApes health score of 43 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ATOS's estimated fair value?

Based on our 5-year discounted cash flow model, ATOSSA THERAPEUTICS, INC.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ATOS undervalued or overvalued?

Our model currently rates ATOS as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ATOS... Refresh in a moment for the full analysis.

ATOSSA THERAPEUTICS, INC. (ATOS)

Healthcare Inconclusive inconclusive weak

$4.47

Updated: 2026-06-06

TradeApes Score

Financial Strength

35 Weak

Operating Trend

45 Mixed

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

80 Strong

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.